Abstract:Approximately 15%-27% of patients with locally advanced rectal cancer (LARC) treated with the neoadjuvant concurrent chemoradiotherapy (nCCRT) could achieve pathological complete remission (pCR). The intestinal microbes participate in the regulation of the oncogenesis, progression and therapeutic effect of gastrointestinal tumors by producing metabolites and toxins, affecting cell proliferation, modulating inflammation and immunity, and inducing DNA damage. Whether the intestinal microbial alterations determine radiosensitivity for patients delivered nCCRT is not clear. We performed a longitudinal study to examine the alterations of rectal and fecal microbiome for patients with LARC patients throughout nCCRT. Serial fecal samples of 39 patients with newly diagnosed LARC were collected at before, 3 weeks during, and after nCCRT. Microbiome characteristics were identified via 16S rDNA sequencing. Responses of the nCCRT were distinguished as "Good" and "Poor" in accordance with "TRG0-1" (tumor regression grade, the AJCC 8th edition) and "TRG2-3" by two independent pathologists. Shannon diversity index (SDI) and Chao1 diversity index (CDI) were used to depict the microbiome diversity and richness. Microbiome's alterations of paired samples at three timepoints throughout nCCRT was analyzed by Wilcoxon signed-rank test. Heatmap shows top two families of each patient's gut microbiome throughout nCCRT. Fecal SDI was significantly decreased at 3 weeks during and after nCCRT (P = 0.01; P = 0.022) while 12 pairs of matched tumoral and peritumoral microbiome before nCCRT treatment showed no difference (P = 0.898). CDI of "Good response" group was obviously higher than "Poor response" in integrated three timepoints (P = 0.0347). 6 of 39 patients had relatively stable dominant bacteria at family level, while the remained 36 demonstrated a sharp variation of dominant bacteria via longitudinal analysis. The abundance of 6 genera Porphyromonas (P = 0.0038), Parvimonas (P<0.001), Peptostreptococcus (P<0.001), Fusobacterium (P<0.001), Ezakiella (P = 0.0017), unidentified_Clostridiales (P = 0.0038) predominantly decreased throughout the whole nCCRT treatment. Fecal microbiome diversity decreased throughout nCCRT and patients of "Good response" had higher richness at integral level. Majority of patients had altered dominant bacteria during the whole nCCRT, while minority remained relatively stable. nCCRT may affect the fecal microbiome and then result in response heterogeneity of LARC patients. The abundance of 6 genera Porphyromonas, Parvimonas, Peptostreptococcus, Fusobacterium, Ezakiella, unidentified_Clostridiales decreased most prominently throughout nCCRT.

Prospective, longitudinal analysis of the gut microbiome in patients with locally advanced rectal cancer predicts response to neoadjuvant concurrent chemoradiotherapy

An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma

Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study

Longitudinal Analysis of Fecal Microbiome Diversity During the Neoadjuvant Concurrent Chemoradiotherapy of Patients with Locally Advanced Rectal Cancer

80MO Gut Microbiome Analysis for Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

Gut Microbiome Predicts Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

Interaction between intratumoral microbiota and tumor mediates the response of neoadjuvant therapy for rectal cancer

Metagenomic Analysis of Intratumoral Microbiome Linking to Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

The Gut Microbiome Is Associated With Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients—A Pilot Study

Relationship between Gut Commensal Bacteria and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Metagenomic analysis reveals effects of gut microbiome in response to neoadjuvant chemoradiotherapy in advanced rectal cancer

Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial.

Prospective Correlation Between the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immunotherapy in Lung Cancer.

Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy

Figure S2 from Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study

Microbial Characteristics of Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiation Therapy According to Pathologic Response

Characterization of the Tumor Microenvironment and Identification of Spatially Predictive Biomarkers Associated with Beneficial Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer

An immuno-score signature of tumor immune microenvironment predicts clinical outcomes in locally advanced rectal cancer